206 related articles for article (PubMed ID: 11406348)
1. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron.
Richardson DR; Mouralian C; Ponka P; Becker E
Biochim Biophys Acta; 2001 May; 1536(2-3):133-40. PubMed ID: 11406348
[TBL] [Abstract][Full Text] [Related]
2. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
3. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
4. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?
Richardson DR
Expert Opin Investig Drugs; 2003 Feb; 12(2):235-45. PubMed ID: 12556217
[TBL] [Abstract][Full Text] [Related]
5. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
Ponka P; Richardson DR; Edward JT; Chubb FL
Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
[TBL] [Abstract][Full Text] [Related]
6. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone.
Ponka P; Grady RW; Wilczynska A; Schulman HM
Biochim Biophys Acta; 1984 Dec; 802(3):477-89. PubMed ID: 6509088
[TBL] [Abstract][Full Text] [Related]
7. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes.
Buss JL; Arduini E; Ponka P
Biochem Pharmacol; 2002 Dec; 64(12):1689-701. PubMed ID: 12445858
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
[TBL] [Abstract][Full Text] [Related]
9. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Richardson DR; Tran EH; Ponka P
Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
[TBL] [Abstract][Full Text] [Related]
10. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe.
Huang AR; Ponka P
Biochim Biophys Acta; 1983 Jun; 757(3):306-15. PubMed ID: 6849979
[TBL] [Abstract][Full Text] [Related]
11. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
12. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
Richardson DR
Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
[TBL] [Abstract][Full Text] [Related]
14. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
15. The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation.
Whitnall M; Suryo Rahmanto Y; Sutak R; Xu X; Becker EM; Mikhael MR; Ponka P; Richardson DR
Proc Natl Acad Sci U S A; 2008 Jul; 105(28):9757-62. PubMed ID: 18621680
[TBL] [Abstract][Full Text] [Related]
16. The potential of the novel NAD
Chiang S; Kalinowski DS; Dharmasivam M; Braidy N; Richardson DR; Huang MLH
Pharmacol Res; 2020 May; 155():104680. PubMed ID: 32032665
[TBL] [Abstract][Full Text] [Related]
17. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
18. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilize iron from reticulocytes in vitro: reappraisal of reported partition coefficients.
Edward JT; Chubb FL; Sangster J
Can J Physiol Pharmacol; 1997 Dec; 75(12):1362-8. PubMed ID: 9534947
[TBL] [Abstract][Full Text] [Related]
19. The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate.
Santos NC; Castilho RF; Meinicke AR; Hermes-Lima M
Eur J Pharmacol; 2001 Sep; 428(1):37-44. PubMed ID: 11779035
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxal isonicotinoyl hydrazone and its analogues.
Buss JL; Hermes-Lima M; Ponka P
Adv Exp Med Biol; 2002; 509():205-29. PubMed ID: 12572996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
